title: Upregulation of PI3K/AKT/mTOR, FABP5 and PPARβ/δ in Human Psoriasis and Imiquimod-induced Murine Psoriasiform Dermatitis Model.
authors.affiliation: Department of Dermatology, School of Medicine and Public Health, University of Wisconsin, 53706 Madison, WI, USA.
authors.forename: Jean Christopher
authors.initials: JC
authors.lastname: Chamcheu
authors.forename: Maria-Ines
authors.initials: MI
authors.lastname: Chaves-Rodriquez
authors.forename: Vaqar M
authors.initials: VM
authors.lastname: Adhami
authors.forename: Imtiaz A
authors.initials: IA
authors.lastname: Siddiqui
authors.forename: Gary S
authors.initials: GS
authors.lastname: Wood
authors.forename: B Jack
authors.initials: BJ
authors.lastname: Longley
authors.forename: Hasan
authors.initials: H
authors.lastname: Mukhtar
mesh_terms: D000634:Aminoquinolines / Q000494:pharmacology*; D000818:Animals; D004195:Disease Models, Animal; D050556:Fatty Acid-Binding Proteins / Q000378:metabolism; D000077271:Imiquimod; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D009363:Neoplasm Proteins / Q000378:metabolism; D047494:PPAR delta / Q000378:metabolism; D048068:PPAR-beta / Q000378:metabolism; D019869:Phosphatidylinositol 3-Kinases / Q000378:metabolism; D051057:Proto-Oncogene Proteins c-akt / Q000378:metabolism; D011565:Psoriasis / Q000139:chemically induced* / Q000378:metabolism*; D058570:TOR Serine-Threonine Kinases / Q000378:metabolism; D015854:Up-Regulation
chemical_list: D000634:Aminoquinolines; D050556:Fatty Acid-Binding Proteins; D000077271:Imiquimod; D009363:Neoplasm Proteins; D047494:PPAR delta; D048068:PPAR-beta; D019869:Phosphatidylinositol 3-Kinases; D051057:Proto-Oncogene Proteins c-akt; D058570:TOR Serine-Threonine Kinases; C082667:Fabp5 protein, mouse; C546842:MTOR protein, human
references.citation: Acta Derm Venereol. 2014 Jul;94(4):371-9
references.pmid: 24217655
references.citation: Biomol Concepts. 2013 Feb;4(1):53-64
references.pmid: 25436565
references.citation: Science. 2005 Feb 18;307(5712):1098-101
references.pmid: 15718470
references.citation: J Invest Dermatol. 2011 Aug;131(8):1684-91
references.pmid: 21490615
references.citation: Br J Dermatol. 2014 Dec;171(6):1533-6
references.pmid: 25041225
references.citation: Future Oncol. 2011 Oct;7(10):1149-67
references.pmid: 21992728
references.citation: Cell. 2012 Apr 13;149(2):274-93
references.pmid: 22500797
references.citation: Biochem Soc Trans. 2012 Feb;40(1):139-46
references.pmid: 22260680
references.citation: Br J Dermatol. 2007 Feb;156(2):372-4
references.pmid: 17223881
references.citation: Arch Biochem Biophys. 2011 Apr 15;508(2):123-37
references.pmid: 21176769
references.citation: J Immunol. 2009 May 1;182(9):5836-45
references.pmid: 19380832
references.citation: Cancer Res. 2009 Mar 1;69(5):1821-7
references.pmid: 19244117
references.citation: Indian J Dermatol. 2014 Jan;59(1):67-70
references.pmid: 24470663
references.citation: N Engl J Med. 2009 Jul 30;361(5):496-509
references.pmid: 19641206
references.citation: J Cell Sci. 1995 Nov;108 ( Pt 11):3463-71
references.pmid: 8586658